Catheter Precision, Inc. · AMEX:VTAK
Catheter Precision — Ra Medical Systems — Investor Presentation (November 2018)
24 slides from Catheter Precision's investor presentation, Nov 13, 2018
Slide 1: Ra Medical Systems Corporate Presentation November 2018
Ra Medical Systems, Inc. NYSE: RMED Corporate Presentation November 2018 Exhibit 99.2
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based on information currently available to management. These forward-l
Slide 3: Ra Medical Snapshot
DABRA—Excimer laser that utilizes disposable catheters for crossing total chronic occlusions (CTOs) and ablating a channel in occlusive peripheral vascular disease. DABRA is used as a tool in the treatment of peripheral artery disease (PAD), a form of peripheral vascular disease. This procedure is c
Slide 4: Highlights
Highlights Single-Use Catheters $1.08B+ Targeted US Annual TAM Among ~17.6M PAD Sufferers in the U.S. Novel Therapeutic Solution with Positive Clinical Study Results Existing US Reimbursement Structure Cost Benefits to Outpatient-Based Catheterization Laboratories and Hospitals Time Efficient and Ea
Slide 5: Peripheral Artery Disease Burden
Up to 180,000 amputations performed annually in the US as a result of PAD Disease Burden Peripheral Artery Disease Atherosclerosis of the lower extremities—most commonly in the legs Smoking, genetic predisposition, diabetes, age and obesity may increase risk Characterized by reduced blood flow to su
Slide 6: Current Treatments and Limitations
Current Treatments and Limitations Non-Invasive Management Lifestyle Changes Often hard to sustain and do not treat underlying cause of disease Pharmacotherapy Generally prescribed for life and do not treat the obstruction, making them ineffective for many More aggressive treatments often required I
Slide 7: DABRA Technology and Mechanism of Action
DABRA Technology and Mechanism of Action DABRA Technology 308 nanometer excimer laser system Unique liquid-filled, full aperture ratio catheter Produces high quality lumen Minimizes mechanical and thermal trauma Mechanism of Action Photochemical ablation, non-thermal Removes blockages by breaking th
Slide 8: Our Solution: DABRA
Our Solution: DABRA Portable Easy to store Intuitive interface Easy calibration Proprietary catheter Features DABRA Can cross and de-bulk wide variety of plaque, unlike some competitors Soft thrombus to hard calcified plaque Tool used by physicians to treat Chronic Total Occlusions (CTOs), unlike so
Slide 9: Clinically Demonstrated Solutions
Clinically Demonstrated Solutions Safety Record Pivotal Study Multi-site study at four sites in US and Mexico Enrolled 64 patients with target blockage refractory to guidewire crossing Primary Efficacy Endpoint: Successful crossing of target lesion based on angiographic analysis at time of procedure
Slide 10: Large US Addressable Market Opportunity
Large US Addressable Market Opportunity PREVALENCE TREATED PATIENTS TOTAL US ATHERECTOMY DEVICE MARKET OPPORTUNITY Current US Market Opportunity KEY DRIVER ~17.6 Million PAD Sufferers in the US Only 20–30% of PAD Patients actively treated Annual US Total Addressable Market (TAM) Opportunity in 2017
Slide 11: Payors and Reimbursement
Payors and Reimbursement Approvals / Clearances DABRA: US FDA 510(k), CE Mark PHAROS: US FDA 510(k), CE Mark, CFDA, KFDA Payor Coverage Reimbursement claims for DABRA procedures typically submitted by providers to Medicare or other third-party payor using established Current Procedural Terminology (
Slide 12: Physician Practice Needs
Physician Practice Needs We believe our solution expands provider economics Ease of Use Versatility Able to cross and debulk Economics Established Safety and Effectiveness
Slide 13: Growth Strategy
Growth Strategy Increase recurring revenues from placing laser units in high volume outpatient-based catheterization laboratories US sales force expansion Expand patient and user awareness Current Expand into hospital catheterization clinics Geographic expansion Near-Term Address new indications Exp
Slide 14: Salesforce Expansion Drives Growth
Salesforce Expansion Drives Growth Incremental Sales Reps Added Q3 2018 5 à Sales Strategy Vascular laser system placements Initial sampling program underway in select markets Account conversion and catheter utilization Direct sales force expansion Call point focused on high volume outpatient-based
Slide 15: Fully Operational Manufacturing Facility
Fully Operational Manufacturing Facility Carlsbad, CA Sizable capacity for laser and catheter production 32,000 sq. ft. Carlsbad, CA with three controlled environments manufacturing facility fully staffed and operational We believe our existing facility is capable of manufacturing over 400 lasers/ye
Slide 16: Pipeline Indications
Pipeline Indications (Not FDA Approved1) PHAROS (Dermatology) Cutaneous T-Cell Lymphoma (CTCL) DABRA (Vascular) Atherectomy (with a pre-specified improvement in luminal patency) Coronary Artery Disease (CAD) In-Stent Restenosis No application has been made to the FDA as of the date hereof for these
Slide 17: Intellectual Property Portfolio
Intellectual Property Portfolio Patents covering several aspects of the laser systems and delivery device The Company believes that its intellectual property comprises novel and useful inventions that can be protected by patents, and as such, has filed patent applications directed to innovative meth
Slide 18: Executive Team and Board of Directors
Executive Team and Board of Directors Dean Irwin Chief Executive Officer, Co-President, Chief Technology Officer Andrew Jackson Chief Financial Officer and Secretary Jeffrey Kraws Co-President Melissa Burstein Executive VP Dan Horwood General Counsel Dean Irwin CEO, Co-President and CTO Ra Medical M
Slide 19: Financial Overview
Financial Overview
Slide 20: Business Model
Business Model Laser Module Capital Placement and Sale DABRATM Catheter Consumable Recurring Revenue Practical, easy to use equipment, anticipated recurring revenue single-use catheter solution
Slide 21: Results of Operations
Results of Operations Year Ended December 31, Nine Months Ended September 30, ($ in thousands) 2017 2016 2018 2017 Vascular Net Revenue $259 $0 $973 $68 Dermatology Net Revenue $5,611 $5,976 $3,296 $3,865 Total Net Revenues $5,870 $5,976 $4,269 $3,933 Gross Profit $1,705 $2,838 $1,263 $1,426 Gross M
Slide 22: Financial Position
Financial Position ($ in thousands) As of September 30, 2018 Cash and Cash Equivalents1 $4,915 Working Capital2 $946 Total Assets $14,189 Long-term Debt $0 Accumulated Deficit $(45,284) Total Stockholders’ Equity $6,481 Excludes $67.3 million net IPO proceeds received October 1, 2018. We define work
Slide 23: Highlights
Highlights Single-Use Catheters $1.08B+ Targeted US Annual TAM Among ~17.6M PAD Sufferers in the U.S. Novel Therapeutic Solution with Positive Clinical Study Results Existing US Reimbursement Structure Cost Benefits to Outpatient-Based Catheterization Laboratories and Hospitals Time Efficient and Ea
Slide 24: Contact
2070 Las Palmas Drive Carlsbad, CA 92011 United States www.ramed.com 760.707.7516 Corporate Presentation NYSE: RMED
Ra Medical Systems — Investor Presentation (November 2018) on 6ix